Editorial: Retinopathy of prematurity in the time of bevacizumab: Incorporating the beat-rop results into clinical practice

Ophthalmology

Volumn 118, Issue 7, 2011, Pages 1227-1228

  Moshfeghi, Darius M ^a   Berrocal, Audina M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

AMBLYOPIA; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GESTATIONAL AGE; HUMAN; LASER COAGULATION; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; TREATMENT OUTCOME; MASS COMMUNICATION; MULTICENTER STUDY (TOPIC); NEOVASCULARIZATION (PATHOLOGY); NEWBORN; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE II AS TOPIC; DIFFUSION OF INNOVATION; HUMANS; INFANT, NEWBORN; MULTICENTER STUDIES AS TOPIC; NEOVASCULARIZATION, PATHOLOGIC; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINOPATHY OF PREMATURITY;

EID: 79959956950     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2011.04.028     Document Type: Editorial

References (12)

1. H.A. Mintz-Hittner, K.A. Kennedy, and A.Z. Chuang Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity N Engl J Med 364 2011 603 615
2. S. Michels, P.J. Rosenfeld, and C.A. Puliafito Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study Ophthalmology 112 2005 1035 1047 (Pubitemid 40797459)
3. V. Compernolle, K. Brusselmans, and T. Acker Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice Nat Med 8 2002 702 710 (Pubitemid 34778723)
4. J. Shahar, R.L. Avery, and G. Heilweil Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin) Retina 26 2006 262 269 (Pubitemid 44318177)
5. K. Miki, A. Miki, and M. Matsuoka Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor Ophthalmology 116 2009 1748 1754
6. R.L. Avery, J. Pearlman, and D.J. Pieramici Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy Ophthalmology 113 2006 1695.e115
7. H. Al-Dhibi, and A.O. Khan Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema J AAPOS 13 2009 400 402
8. R.L. Avery Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern J AAPOS 13 2009 329 331
9. R.J. Hairston, A.M. Maguire, S. Vitale, and W.R. Green Morphometric analysis of pars plana development in humans Retina 17 1997 135 138 (Pubitemid 27188311)
10. A. Vinekar, M.T. Trese, and A. Capone Jr Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach Am J Ophthalmol 145 2008 548 555
11. Section on Ophthalmology American Academy of Pediatrics; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus Screening examination of premature infants for retinopathy of prematurity Pediatrics 117 2006 572 576
12. D.K. Coats, A.M. Miller, and K.M. Brady McCreery Involution of threshold retinopathy of prematurity after diode laser photocoagulation Ophthalmology 111 2004 1894 1898 (Pubitemid 39311843)